
Bristol Myers Squibb stays a Strong Buy with steady dividends and growth despite some challenges.
Bristol Myers Squibb (BMY) is rated a Strong Buy due to its steady performance and undervaluation, despite recent underperformance against the market benchmark. The company offers a 4.43% forward dividend yield, more than double the sector median, wi...



